Extensive carotid atherosclerosis and the diagnostic accuracy of coronary risk calculators

Michel Romanens, Martin Bødtker Mortensen, Isabella Sudano, Thomas Szucs, Ansgar Adams, Michel Romanens, Martin Bødtker Mortensen, Isabella Sudano, Thomas Szucs, Ansgar Adams

Abstract

Preventive therapy in primary care is guided by risk thresholds for future cardiovascular events. We aimed to assess whether the sensitivity of various risk calculators for the detection of subclinical carotid atherosclerosis (TPA80) could be improved by lowering risk thresholds in younger age groups. We compared sensitivity, specificity, and discriminatory performance of SCORE, SCORE-HDL, PROCAM, AGLA, FRAM and PCE coronary risk calculators to detect total plaque area > 80 mm2 (TPA80), a coronary risk equivalent, in age groups 40-55, 56-65, 66-75 from Germany (DE, N = 2942) and Switzerland (CH, N = 2202) during the years 2002 to 2016. All calculators showed good to moderate discriminatory performance to detect TPA80 with AUC ranging from 0.74 (CH-AGLA) to 0.87 (DE- SCORE), but the sensitivity of high risk risk thresholds varied widely from 39% for DE-FRAM-CVD to 5% for CH-AGLA. Lowering of the risk threshold increased sensitivity substantially at the expense of minor losses in specificity, but the sensitivity generally remained < 45% at the 90% specificity threshold. Current risk thresholds of American and European coronary risk calculators have a low sensitivity to detect TPA80 in younger individuals.

Keywords: Atherosclerosis; Carotid plaque; Risk-prediction; Statin-indication.

Figures

Fig. 1
Fig. 1
Summarized discriminatory performance of FRAM-CVD, SCORE-CVD, PCE and PROCAM coronary risk calculators to detect total plaque area > 80 mm2 (TPA80) in 5′144 primary prevention subjects.

References

    1. Adams A., Bojara W. Vorhersage einer stenosierenden KHK durch Bestimmung von Plaque-Fläche und -Dicke vs. IMT an der A. carotis. Herz. 2015;1–5
    1. Arbab-Zadeh A., Fuster V. The Myth of the “Vulnerable Plaque”. J. Am. Coll. Cardiol. 2015;65:846–855.
    1. Assmann G., Schulte H., Cullen P., Seedorf U. Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study. Eur. J. Clin. Investig. 2007;37:925–932.
    1. Baber U., Mehran R., Sartori S. Detection and impact of subclinical coronary and carotid atherosclerosis on cardiovascular risk prediction and reclassification in asymptomatic us adults: insights from the high risk plaque Bioimage study. J. Am. Coll. Cardiol. 2014;63:A998.
    1. Bogiatzi C., Spence J.D. Ezetimibe and regression of carotid atherosclerosis: importance of measuring plaque burden. Stroke. 2012;43:1153–1155.
    1. Cannon C.P., Blazing M.A., Giugliano R.P. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N. Engl. J. Med. 2015;372:2387–2397.
    1. Conroy R.M., Pyörälä K., Fitzgerald A.P. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart J. 2003;24:987–1003.
    1. Cooney M.T., Dudina A., De Bacquer D. HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. Atherosclerosis. 2009;206:611–616.
    1. D'Agostino RB, Vasan RS, Pencina MJ, Wolf P A, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743–53.
    1. De Backer G., Ambrosioni E., Borch-Johnsen K. European guidelines on cardiovascular disease prevention in clinical practice - third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiov Prev R. 2003;10:1–10.
    1. DeFilippis A.P., Young R., Carrubba C.J. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann. Intern. Med. 2015;162:266–275.
    1. Descamps O.S., Cooney M.T., De Backer G., Graham I. A simple multiplier to calculate the impact of HDL cholesterol on cardiovascular risk estimation using SCORE. Atherosclerosis. 2012;222:564–566.
    1. Eckardstein A. AGLA Guidelines [Internet] 2014. [cited 2016 Aug 1];Available from.
    1. Gottesman R.F., Schneider A.L.C., Albert M. Midlife hypertension and 20-year cognitive change: the atherosclerosis risk in communities neurocognitive study. JAMA Neurol. 2014;71:1218–1227.
    1. Hald E.M., Lijfering W.M., Mathiesen E.B. Carotid atherosclerosis predicts future myocardial infarction but not venous thromboembolism: the Tromso study. Arterioscler. Thromb. Vasc. Biol. 2013;34:226–230.
    1. Johnson K.M., Dowe D.A. Accuracy of Statin Assignment Using the 2013 AHA/ACC Cholesterol Guideline Versus the 2001 NCEP ATP III Guideline. J. Am. Coll. Cardiol. 2014;64:910–919.
    1. Kokkinos P.F., Faselis C., Myers J., Panagiotakos D., Doumas M. Vol. 6736. 2012. Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study; pp. 10–15.
    1. Mansia G., De Backer G., Dominiczak A. 2007 ESH-ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Blood Press. 2007;16:135–232.
    1. Mc Connachie A., Walker A., Robertson M. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. Eur. Heart J. 2014;35:290–298.
    1. McEvoy J.W., Diamond G.A., Detrano R.C. Risk and the physics of clinical prediction. Am. J. Cardiol. 2014;113:1429–1435.
    1. MedCalc Software bvba, Ostend B. MedCalc Statistical Software version [Internet]. 2013;Available from:
    1. Mortensen M.B., Falk E. Real-life evaluation of European and American high-risk strategies for primary prevention of cardiovascular disease in patients with first myocardial infarction. BMJ Open. 2014;4:1–8.
    1. Mortensen M.B., Afzal S., Nordestgaard B.G., Falk E. The high-density lipoprotein-adjusted SCORE model worsens SCORE-based risk classification in a contemporary population of 30 824 Europeans: the Copenhagen General Population Study. Eur. Heart J. 2015;36:2446–2453.
    1. Mortensen M.B., Nordestgaard B.G., Afzal S., Falk E. ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen General Population Study. Eur. Heart J. 2017;38:586–594.
    1. Navar-Boggan A.M., Peterson E.D., D'Agostino R.B., Pencina M.J., Sniderman A.D. One size may not fit all: using age- and sex-specific risk thresholds to guide statin therapy. J. Am. Coll. Cardiol. 2015;65:1633–1639.
    1. Navar-Boggan A.M., Peterson E.D., D'Agostino R.B., Neely B., Sniderman A.D., Pencina M.J. Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease. Circulation. 2015;131:451–458.
    1. Robinson J.G., Stone N.J. The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence. Eur. Heart J. 2015;2110–2118
    1. Romanens M. 2016. VARIFO Cardiovascular Risk Calculator. Available from: .
    1. Romanens M., Ackermann F., Sudano I. LDL-cholesterol and the potential for coronary risk improvement. Kardiovaskuläre Medizin. 2011;14:345–350.
    1. Romanens M., Ackermann F., Sudano I., Szucs T., Spence J.D. Arterial age as a substitute for chronological age in the AGLA risk function could improve coronary risk prediction. Swiss Med. Wkly. 2014;1–7
    1. Spence J.D. Is carotid intima-media thickness a reliable clinical predictor? Mayo Clin. Proc. 2008;83:1299–1300.
    1. Spence J.D. Carotid plaque measurement is superior to IMT. Atherosclerosis. 2012;220:34–35.
    1. Spence D., Hackam D. Treating arteries instead of risk factors: a paradigm change in management of atherosclerosis. Stroke. 2010;41:1193–1199.
    1. Spence J.D., Eliasziw M., DiCicco M., Hackam D.G., Galil R., Lohmann T. Carotid plaque area: a tool for targeting and evaluating vascular preventive therapy. Stroke. 2002;33:2916–2922.
    1. Stone N.J., Robinson J.G., Lichtenstein A.H. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. J. Am. Coll. Cardiol. 2014;63:2889–2934.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅